Your browser doesn't support javascript.
loading
節目: 20 | 50 | 100
结果 1 - 1 de 1
过滤器
添加過濾器








年份範圍
1.
Int. braz. j. urol ; 39(5): 614-621, Sep-Oct/2013. tab, graf
文章 在 英语 | LILACS | ID: lil-695167

摘要

Purpose To report the outcomes of patients with pathologic T4 UTUC and investigate the potential impact of peri-operative chemotherapy combined with radical nephroureterectomy (RNU) and regional lymph node dissection (LND) on oncologic outcomes. Materials and Methods Patients with pathologic T4 UTUC were identified from the cohort of 1464 patients treated with RNU at 13 academic centers between 1987 and 2007. Oncologic outcomes were stratified according to utilization of perioperative systemic chemotherapy and regional LND as an adjunct to RNU. Results The study included 69 patients, 42 males (61%) with median age 73 (range 43-98). Median follow-up was 17 months (range: 6-88). Lymphovascular invasion was found in 47 (68%) and regional lymph node metastases were found in 31 (45%). Peri-operative chemotherapy was utilized in 29 (42%) patients. Patients treated with peri-operative chemotherapy and RNU with LND demonstrated superior oncologic outcomes compared to those not treated by chemotherapy and/or LND during RNU (3Y-DFS: 35% vs. 10%; P = 0.02 and 3Y-CSS: 28% vs. 14%; P = 0.08). In multivariate Cox regression analysis, administration of peri-operative chemotherapy and utilization of LND during RNU was associated with lower probability of recurrence (HR: 0.4, P = 0.01), and cancer specific mortality (HR: 0.5, P = 0.06). Conclusions Pathological T4 UTUC is associated with poor prognosis. Peri-operative chemotherapy combined with aggressive surgery, including lymph node dissection, may improve oncological outcomes. Our findings support the use of aggressive multimodal treatment in patients with advanced UTUC. .


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Carcinoma/drug therapy , Carcinoma/surgery , Nephrectomy/methods , Ureter/surgery , Urologic Neoplasms/drug therapy , Urologic Neoplasms/surgery , Antineoplastic Agents/therapeutic use , Combined Modality Therapy , Carcinoma/pathology , Disease-Free Survival , Kaplan-Meier Estimate , Lymph Node Excision , Neoplasm Staging , Neoplasm Recurrence, Local/pathology , Regression Analysis , Time Factors , Treatment Outcome , Urologic Neoplasms/pathology
搜索明细